Literature DB >> 27383016

FGFs: crucial factors that regulate tumour initiation and progression.

Qian Jing1, Yuanyuan Wang1, Hao Liu1, Xiaowei Deng1, Lin Jiang1, Rui Liu2, Haixing Song1, Jingyi Li1.   

Abstract

Fibroblast growth factors (FGFs) are crucial signalling molecules involved in normal cell growth, differentiation and proliferation. Over the past few decades, a large body of research has illustrated effects of individual FGFs on tumour initiation and progression. Tumour development is commonly accompanied with generation of new blood and lymph vessels, which support enhanced cell proliferation. Moreover, acquisition of tumour cells of the epithelial-mesenchymal transition (EMT) phenotype, enhances tumour cell migration and invasion potentials, crucial steps in tumour metastasis. This review summarizes recent findings concerning roles of FGFs in angiogenesis, lymphangiogenesis and EMT.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27383016      PMCID: PMC6496028          DOI: 10.1111/cpr.12275

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  122 in total

Review 1.  Immune cells as a source and target of angiogenic and lymphangiogenic factors.

Authors:  Stefania Loffredo; Rosaria Ilaria Staiano; Francescopaolo Granata; Arturo Genovese; Gianni Marone
Journal:  Chem Immunol Allergy       Date:  2013-10-17

Review 2.  Pressing the right buttons: signaling in lymphangiogenesis.

Authors:  Sanja Coso; Esther Bovay; Tatiana V Petrova
Journal:  Blood       Date:  2014-03-07       Impact factor: 22.113

3.  Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation.

Authors:  K C Hart; S C Robertson; D J Donoghue
Journal:  Mol Biol Cell       Date:  2001-04       Impact factor: 4.138

4.  A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  David Bender; Michael W Sill; Heather A Lankes; Henry D Reyes; Christopher J Darus; James E Delmore; Jacob Rotmensch; Heidi J Gray; Robert S Mannel; Jeanne M Schilder; Mark I Hunter; Carolyn K McCourt; Megan I Samuelson; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2015-07-15       Impact factor: 5.482

5.  1α,25(OH)₂D₃ inhibits FGF-2 release from oral squamous cell carcinoma cells through down-regulation of HBp17/FGFBP-1.

Authors:  S N Zawani B Rosli; Tomoaki Shintani; Shigeaki Toratani; Emiko Usui; Tetsuji Okamoto
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-06-18       Impact factor: 2.416

Review 6.  Exploring mechanisms of FGF signalling through the lens of structural biology.

Authors:  Regina Goetz; Moosa Mohammadi
Journal:  Nat Rev Mol Cell Biol       Date:  2013-02-13       Impact factor: 94.444

7.  Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.

Authors:  Tram Anh Tran; Hon Sing Leong; Andrea Pavia-Jimenez; Slavic Fedyshyn; Juan Yang; Blanka Kucejova; Sharanya Sivanand; Patrick Spence; Xian-Jin Xie; Samuel Peña-Llopis; Nicholas Power; James Brugarolas
Journal:  Mol Cell Biol       Date:  2016-06-15       Impact factor: 4.272

Review 8.  Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases.

Authors:  Masabumi Shibuya
Journal:  J Biochem       Date:  2012-11-21       Impact factor: 3.387

Review 9.  Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?

Authors:  Christine Heinzle; Zeynep Erdem; Jakob Paur; Bettina Grasl-Kraupp; Klaus Holzmann; Michael Grusch; Walter Berger; Brigitte Marian
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

10.  FGF10: Type III Epithelial Mesenchymal Transition and Invasion in Breast Cancer Cell Lines.

Authors:  Ali Abolhassani; Gholam Hossein Riazi; Ebrahim Azizi; Saeid Amanpour; Samad Muhammadnejad; Mahnaz Haddadi; Ali Zekri; Reza Shirkoohi
Journal:  J Cancer       Date:  2014-06-21       Impact factor: 4.207

View more
  1 in total

1.  Germline Variants in Angiogenesis-Related Genes Contribute to Clinical Outcome in Head and Neck Squamous Cell Carcinoma.

Authors:  Dorota Butkiewicz; Agnieszka Gdowicz-Kłosok; Małgorzata Krześniak; Tomasz Rutkowski; Barbara Łasut-Szyszka; Krzysztof Składowski
Journal:  Cancers (Basel)       Date:  2022-04-06       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.